Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults.

Mehta T, Buzkova P, Kizer JR, Djousse L, Chonchol M, Mukamal KJ, Shlipak M, Ix JH, Jalal D.

BMC Nephrol. 2017 Mar 21;18(1):98. doi: 10.1186/s12882-017-0509-6.

2.

Rodent models of diabetic nephropathy: their utility and limitations.

Kitada M, Ogura Y, Koya D.

Int J Nephrol Renovasc Dis. 2016 Nov 14;9:279-290. eCollection 2016. Review.

3.

Involvement of Histone Lysine Methylation in p21 Gene Expression in Rat Kidney In Vivo and Rat Mesangial Cells In Vitro under Diabetic Conditions.

Li X, Li C, Li X, Cui P, Li Q, Guo Q, Han H, Liu S, Sun G.

J Diabetes Res. 2016;2016:3853242. doi: 10.1155/2016/3853242. Epub 2016 Aug 29.

4.

Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.

Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, Greene T, Blumenthal SS, Rychlik I, Yagil Y, Zaoui P, Lewis JB.

J Am Soc Nephrol. 2017 Mar;28(3):953-962. doi: 10.1681/ASN.2015111230. Epub 2016 Sep 19.

PMID:
27647855
5.

Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease.

Miranda-Díaz AG, Pazarín-Villaseñor L, Yanowsky-Escatell FG, Andrade-Sierra J.

J Diabetes Res. 2016;2016:7047238. doi: 10.1155/2016/7047238. Epub 2016 Jul 20. Review.

6.

Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria.

Liang X, Schnaper HW, Matsusaka T, Pastan I, Ledbetter S, Hayashida T.

PLoS One. 2016 May 17;11(5):e0155534. doi: 10.1371/journal.pone.0155534. eCollection 2016.

7.

Stop chronic kidney disease progression: Time is approaching.

Sharaf El Din UA, Salem MM, Abdulazim DO.

World J Nephrol. 2016 May 6;5(3):258-73. doi: 10.5527/wjn.v5.i3.258. Review.

8.

Podocytes: the Weakest Link in Diabetic Kidney Disease?

Lin JS, Susztak K.

Curr Diab Rep. 2016 May;16(5):45. doi: 10.1007/s11892-016-0735-5. Review.

PMID:
27053072
9.

Serum TGF-β1 as a Biomarker for Type 2 Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials.

Mou X, Zhou DY, Zhou DY, Ma JR, Liu YH, Chen HP, Hu YB, Shou CM, Chen JW, Liu WH, Ma GL.

PLoS One. 2016 Feb 22;11(2):e0149513. doi: 10.1371/journal.pone.0149513. eCollection 2016. Review.

10.

Hypoxia: The Force that Drives Chronic Kidney Disease.

Fu Q, Colgan SP, Shelley CS.

Clin Med Res. 2016 Mar;14(1):15-39. doi: 10.3121/cmr.2015.1282. Epub 2016 Feb 4. Review.

11.

Dynamin-Related Protein 1 Deficiency Improves Mitochondrial Fitness and Protects against Progression of Diabetic Nephropathy.

Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, Danesh FR.

J Am Soc Nephrol. 2016 Sep;27(9):2733-47. doi: 10.1681/ASN.2015101096. Epub 2016 Jan 29.

PMID:
26825530
12.

TGF-β signaling in the kidney: profibrotic and protective effects.

Sureshbabu A, Muhsin SA, Choi ME.

Am J Physiol Renal Physiol. 2016 Apr 1;310(7):F596-F606. doi: 10.1152/ajprenal.00365.2015. Epub 2016 Jan 6. Review.

13.

Transforming growth factor-β1 and diabetic nephropathy.

Chang AS, Hathaway CK, Smithies O, Kakoki M.

Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F689-F696. doi: 10.1152/ajprenal.00502.2015. Epub 2015 Dec 30. Review.

14.

Histological changes of kidney in diabetic nephropathy.

Pourghasem M, Shafi H, Babazadeh Z.

Caspian J Intern Med. 2015 Summer;6(3):120-7. Review.

15.

Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.

Abou Msallem J, Chalhoub H, Al-Hariri M, Saad L, Jaffa MA, Ziyadeh FN, Jaffa AA.

Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F980-90. doi: 10.1152/ajprenal.00233.2015. Epub 2015 Oct 7. Retraction in: Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F967.

16.

Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

Johnson SA, Spurney RF.

Am J Physiol Renal Physiol. 2015 Nov 15;309(10):F807-20. doi: 10.1152/ajprenal.00266.2015. Epub 2015 Sep 2. Review.

17.

Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies.

Zeisberg M, Zeisberg EM.

Fibrogenesis Tissue Repair. 2015 Sep 1;8:16. doi: 10.1186/s13069-015-0033-x. eCollection 2015.

18.

Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling.

Han Y, Lu JS, Xu Y, Zhang L, Hong BF.

Int J Clin Exp Pathol. 2015 May 1;8(5):4725-34. eCollection 2015.

19.

TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2.

Rodrigues-Díez R, Rayego-Mateos S, Orejudo M, Aroeira LS, Selgas R, Ortiz A, Egido J, Ruiz-Ortega M.

Mediators Inflamm. 2015;2015:506041. doi: 10.1155/2015/506041. Epub 2015 May 5.

20.

Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation.

Thakur S, Viswanadhapalli S, Kopp JB, Shi Q, Barnes JL, Block K, Gorin Y, Abboud HE.

Am J Pathol. 2015 Aug;185(8):2168-80. doi: 10.1016/j.ajpath.2015.04.014. Epub 2015 Jun 10.

Supplemental Content

Support Center